Shares in Cepheid rose 17.8 percent for the five-day trading period ended Tuesday, following last week’s clearance by the US Food and Drug Administration of the firm’s meningitis molecular diagnostic assay. The test is Cepheid’s third molecular diagnostic product cleared by the FDA for sale in the US.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.